nodes	percent_of_prediction	percent_of_DWPC	metapath
Amcinonide—Corticosteroid Hormone Receptor Agonists—Prednisone—systemic scleroderma	0.317	1	CiPCiCtD
Amcinonide—Mometasone—systemic scleroderma	0.196	0.647	CrCtD
Amcinonide—Prednisone—systemic scleroderma	0.107	0.353	CrCtD
Amcinonide—NR3C1—Mometasone—systemic scleroderma	0.0943	0.759	CbGbCtD
Amcinonide—NR3C1—Prednisone—systemic scleroderma	0.03	0.241	CbGbCtD
Amcinonide—Fluticasone furoate—Mometasone—systemic scleroderma	0.00786	0.0368	CrCrCtD
Amcinonide—Flumethasone Pivalate—Mometasone—systemic scleroderma	0.00707	0.033	CrCrCtD
Amcinonide—Difluprednate—Mometasone—systemic scleroderma	0.00684	0.032	CrCrCtD
Amcinonide—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00684	0.032	CrCrCtD
Amcinonide—Halobetasol Propionate—Mometasone—systemic scleroderma	0.00684	0.032	CrCrCtD
Amcinonide—Fluocinonide—Mometasone—systemic scleroderma	0.00643	0.0301	CrCrCtD
Amcinonide—Prednicarbate—Mometasone—systemic scleroderma	0.00643	0.0301	CrCrCtD
Amcinonide—Beclomethasone—Mometasone—systemic scleroderma	0.00643	0.0301	CrCrCtD
Amcinonide—Fluocinolone Acetonide—Mometasone—systemic scleroderma	0.00607	0.0284	CrCrCtD
Amcinonide—Budesonide—Mometasone—systemic scleroderma	0.00591	0.0276	CrCrCtD
Amcinonide—Fluoxymesterone—Mometasone—systemic scleroderma	0.00591	0.0276	CrCrCtD
Amcinonide—Desonide—Mometasone—systemic scleroderma	0.00576	0.0269	CrCrCtD
Amcinonide—Prednisone—Mometasone—systemic scleroderma	0.00576	0.0269	CrCrCtD
Amcinonide—Clobetasol propionate—Mometasone—systemic scleroderma	0.00576	0.0269	CrCrCtD
Amcinonide—Flunisolide—Mometasone—systemic scleroderma	0.00576	0.0269	CrCrCtD
Amcinonide—Fludrocortisone—Mometasone—systemic scleroderma	0.00576	0.0269	CrCrCtD
Amcinonide—Diflorasone—Mometasone—systemic scleroderma	0.00576	0.0269	CrCrCtD
Amcinonide—Desoximetasone—Mometasone—systemic scleroderma	0.00548	0.0256	CrCrCtD
Amcinonide—Fluorometholone—Mometasone—systemic scleroderma	0.00535	0.025	CrCrCtD
Amcinonide—Triamcinolone—Mometasone—systemic scleroderma	0.00535	0.025	CrCrCtD
Amcinonide—Fluprednidene Acetate—Mometasone—systemic scleroderma	0.00535	0.025	CrCrCtD
Amcinonide—Loteprednol—Mometasone—systemic scleroderma	0.00535	0.025	CrCrCtD
Amcinonide—Dexamethasone—Mometasone—systemic scleroderma	0.00523	0.0244	CrCrCtD
Amcinonide—Rimexolone—Mometasone—systemic scleroderma	0.00523	0.0244	CrCrCtD
Amcinonide—Betamethasone—Mometasone—systemic scleroderma	0.00523	0.0244	CrCrCtD
Amcinonide—Prednisolone—Mometasone—systemic scleroderma	0.00489	0.0229	CrCrCtD
Amcinonide—Ciclesonide—Prednisone—systemic scleroderma	0.00446	0.0208	CrCrCtD
Amcinonide—Cortisone acetate—Prednisone—systemic scleroderma	0.00361	0.0169	CrCrCtD
Amcinonide—Prednicarbate—Prednisone—systemic scleroderma	0.00351	0.0164	CrCrCtD
Amcinonide—Budesonide—Prednisone—systemic scleroderma	0.00322	0.0151	CrCrCtD
Amcinonide—Desonide—Prednisone—systemic scleroderma	0.00314	0.0147	CrCrCtD
Amcinonide—Fludrocortisone—Prednisone—systemic scleroderma	0.00314	0.0147	CrCrCtD
Amcinonide—Flunisolide—Prednisone—systemic scleroderma	0.00314	0.0147	CrCrCtD
Amcinonide—Diflorasone—Prednisone—systemic scleroderma	0.00314	0.0147	CrCrCtD
Amcinonide—Clobetasol propionate—Prednisone—systemic scleroderma	0.00314	0.0147	CrCrCtD
Amcinonide—Desoximetasone—Prednisone—systemic scleroderma	0.00299	0.014	CrCrCtD
Amcinonide—Fluprednidene Acetate—Prednisone—systemic scleroderma	0.00292	0.0136	CrCrCtD
Amcinonide—Mometasone—Prednisone—systemic scleroderma	0.00292	0.0136	CrCrCtD
Amcinonide—Triamcinolone—Prednisone—systemic scleroderma	0.00292	0.0136	CrCrCtD
Amcinonide—Fluorometholone—Prednisone—systemic scleroderma	0.00292	0.0136	CrCrCtD
Amcinonide—Loteprednol—Prednisone—systemic scleroderma	0.00292	0.0136	CrCrCtD
Amcinonide—Betamethasone—Prednisone—systemic scleroderma	0.00285	0.0133	CrCrCtD
Amcinonide—Rimexolone—Prednisone—systemic scleroderma	0.00285	0.0133	CrCrCtD
Amcinonide—Dexamethasone—Prednisone—systemic scleroderma	0.00285	0.0133	CrCrCtD
Amcinonide—Prednisolone—Prednisone—systemic scleroderma	0.00267	0.0125	CrCrCtD
Amcinonide—Secondary adrenocortical insufficiency—Mometasone—systemic scleroderma	0.00254	0.0749	CcSEcCtD
Amcinonide—Dermatitis perioral—Mometasone—systemic scleroderma	0.00194	0.0572	CcSEcCtD
Amcinonide—Telangiectasia—Mometasone—systemic scleroderma	0.00187	0.0551	CcSEcCtD
Amcinonide—Acneiform eruption—Mometasone—systemic scleroderma	0.00174	0.0514	CcSEcCtD
Amcinonide—Secondary infection—Mometasone—systemic scleroderma	0.0015	0.0442	CcSEcCtD
Amcinonide—Miliaria—Mometasone—systemic scleroderma	0.0015	0.0442	CcSEcCtD
Amcinonide—Skin atrophy—Mometasone—systemic scleroderma	0.00146	0.043	CcSEcCtD
Amcinonide—Skin striae—Mometasone—systemic scleroderma	0.00138	0.0408	CcSEcCtD
Amcinonide—Dermatitis acneiform—Mometasone—systemic scleroderma	0.00129	0.038	CcSEcCtD
Amcinonide—Allergic contact dermatitis—Mometasone—systemic scleroderma	0.00126	0.0372	CcSEcCtD
Amcinonide—Hypertrichosis—Mometasone—systemic scleroderma	0.00116	0.0342	CcSEcCtD
Amcinonide—Secondary infection—Azathioprine—systemic scleroderma	0.00115	0.0339	CcSEcCtD
Amcinonide—Leukoderma—Mometasone—systemic scleroderma	0.00104	0.0306	CcSEcCtD
Amcinonide—Secondary adrenocortical insufficiency—Prednisone—systemic scleroderma	0.000937	0.0277	CcSEcCtD
Amcinonide—Atrophy—Mycophenolic acid—systemic scleroderma	0.000932	0.0275	CcSEcCtD
Amcinonide—Atrophy—Mycophenolate mofetil—systemic scleroderma	0.000736	0.0217	CcSEcCtD
Amcinonide—Folliculitis—Mometasone—systemic scleroderma	0.0007	0.0207	CcSEcCtD
Amcinonide—Telangiectasia—Prednisone—systemic scleroderma	0.00069	0.0204	CcSEcCtD
Amcinonide—ANXA1—Spinal Cord Injury—AIF1—systemic scleroderma	0.000663	0.135	CbGpPWpGaD
Amcinonide—Acneiform eruption—Prednisone—systemic scleroderma	0.000644	0.019	CcSEcCtD
Amcinonide—Cataract subcapsular—Prednisone—systemic scleroderma	0.000623	0.0184	CcSEcCtD
Amcinonide—Telangiectasia—Methotrexate—systemic scleroderma	0.000577	0.017	CcSEcCtD
Amcinonide—Stinging—Mometasone—systemic scleroderma	0.000543	0.016	CcSEcCtD
Amcinonide—Skin atrophy—Prednisone—systemic scleroderma	0.000538	0.0159	CcSEcCtD
Amcinonide—Skin striae—Prednisone—systemic scleroderma	0.000511	0.0151	CcSEcCtD
Amcinonide—Atrophy—Prednisone—systemic scleroderma	0.000499	0.0147	CcSEcCtD
Amcinonide—Dermatitis acneiform—Prednisone—systemic scleroderma	0.000476	0.014	CcSEcCtD
Amcinonide—Dermatitis contact—Mometasone—systemic scleroderma	0.000435	0.0128	CcSEcCtD
Amcinonide—ANXA1—connective tissue—systemic scleroderma	0.000435	0.154	CbGeAlD
Amcinonide—Hypertrichosis—Prednisone—systemic scleroderma	0.000428	0.0126	CcSEcCtD
Amcinonide—ANXA1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.000411	0.0835	CbGpPWpGaD
Amcinonide—ANXA1—smooth muscle tissue—systemic scleroderma	0.000398	0.141	CbGeAlD
Amcinonide—ANXA1—skin of body—systemic scleroderma	0.000392	0.139	CbGeAlD
Amcinonide—Leukoderma—Prednisone—systemic scleroderma	0.000382	0.0113	CcSEcCtD
Amcinonide—Rash pustular—Mycophenolic acid—systemic scleroderma	0.000381	0.0112	CcSEcCtD
Amcinonide—ANXA1—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000324	0.0657	CbGpPWpGaD
Amcinonide—Leukoderma—Methotrexate—systemic scleroderma	0.00032	0.00943	CcSEcCtD
Amcinonide—Dermatitis contact—Leflunomide—systemic scleroderma	0.000315	0.00929	CcSEcCtD
Amcinonide—ANXA1—digestive system—systemic scleroderma	0.000314	0.111	CbGeAlD
Amcinonide—Rash pustular—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00888	CcSEcCtD
Amcinonide—ANXA1—tendon—systemic scleroderma	0.000299	0.106	CbGeAlD
Amcinonide—ANXA1—Spinal Cord Injury—SELP—systemic scleroderma	0.000288	0.0586	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000286	0.0581	CbGpPWpGaD
Amcinonide—ANXA1—Spinal Cord Injury—RHOB—systemic scleroderma	0.000269	0.0547	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000266	0.054	CbGpPWpGaD
Amcinonide—ANXA1—lung—systemic scleroderma	0.000262	0.0927	CbGeAlD
Amcinonide—Folliculitis—Methotrexate—systemic scleroderma	0.000216	0.00638	CcSEcCtD
Amcinonide—Infection—Pentoxifylline—systemic scleroderma	0.000181	0.00534	CcSEcCtD
Amcinonide—Infection—Mometasone—systemic scleroderma	0.000156	0.0046	CcSEcCtD
Amcinonide—NR3C1—connective tissue—systemic scleroderma	0.000151	0.0534	CbGeAlD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000149	0.0302	CbGpPWpGaD
Amcinonide—NR3C1—smooth muscle tissue—systemic scleroderma	0.000138	0.0488	CbGeAlD
Amcinonide—ANXA1—Spinal Cord Injury—IL1A—systemic scleroderma	0.000137	0.0278	CbGpPWpGaD
Amcinonide—NR3C1—skin of body—systemic scleroderma	0.000136	0.0482	CbGeAlD
Amcinonide—Pain—Mometasone—systemic scleroderma	0.000134	0.00396	CcSEcCtD
Amcinonide—Pruritus—Pentoxifylline—systemic scleroderma	0.000129	0.0038	CcSEcCtD
Amcinonide—NR3C1—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000122	0.0248	CbGpPWpGaD
Amcinonide—Infection—Azathioprine—systemic scleroderma	0.00012	0.00353	CcSEcCtD
Amcinonide—Dermatitis—Pentoxifylline—systemic scleroderma	0.000115	0.00338	CcSEcCtD
Amcinonide—Infection—Leflunomide—systemic scleroderma	0.000113	0.00333	CcSEcCtD
Amcinonide—Pruritus—Mometasone—systemic scleroderma	0.000111	0.00328	CcSEcCtD
Amcinonide—NR3C1—digestive system—systemic scleroderma	0.000109	0.0386	CbGeAlD
Amcinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000108	0.022	CbGpPWpGaD
Amcinonide—Infection—Mycophenolic acid—systemic scleroderma	0.000108	0.00318	CcSEcCtD
Amcinonide—NR3C1—tendon—systemic scleroderma	0.000104	0.0367	CbGeAlD
Amcinonide—Dermatitis—Mometasone—systemic scleroderma	9.89e-05	0.00292	CcSEcCtD
Amcinonide—Pruritus—Captopril—systemic scleroderma	9.76e-05	0.00288	CcSEcCtD
Amcinonide—Pain—Leflunomide—systemic scleroderma	9.72e-05	0.00287	CcSEcCtD
Amcinonide—Infection—Lisinopril—systemic scleroderma	9.7e-05	0.00286	CcSEcCtD
Amcinonide—ANXA1—G alpha (q) signalling events—EDN1—systemic scleroderma	9.51e-05	0.0193	CbGpPWpGaD
Amcinonide—ANXA1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	9.49e-05	0.0193	CbGpPWpGaD
Amcinonide—ANXA1—Spinal Cord Injury—CCL2—systemic scleroderma	9.4e-05	0.0191	CbGpPWpGaD
Amcinonide—ANXA1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	9.39e-05	0.0191	CbGpPWpGaD
Amcinonide—Pain—Mycophenolic acid—systemic scleroderma	9.27e-05	0.00274	CcSEcCtD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	9.18e-05	0.0187	CbGpPWpGaD
Amcinonide—NR3C1—lung—systemic scleroderma	9.11e-05	0.0322	CbGeAlD
Amcinonide—Dermatitis—Captopril—systemic scleroderma	8.69e-05	0.00256	CcSEcCtD
Amcinonide—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	8.51e-05	0.0173	CbGpPWpGaD
Amcinonide—Infection—Mycophenolate mofetil—systemic scleroderma	8.5e-05	0.00251	CcSEcCtD
Amcinonide—Pain—Lisinopril—systemic scleroderma	8.35e-05	0.00246	CcSEcCtD
Amcinonide—Pruritus—Leflunomide—systemic scleroderma	8.04e-05	0.00237	CcSEcCtD
Amcinonide—Pruritus—Mycophenolic acid—systemic scleroderma	7.67e-05	0.00226	CcSEcCtD
Amcinonide—Dermatitis—Azathioprine—systemic scleroderma	7.58e-05	0.00224	CcSEcCtD
Amcinonide—Pain—Mycophenolate mofetil—systemic scleroderma	7.32e-05	0.00216	CcSEcCtD
Amcinonide—Dermatitis—Leflunomide—systemic scleroderma	7.16e-05	0.00211	CcSEcCtD
Amcinonide—ANXA1—Spinal Cord Injury—IL1B—systemic scleroderma	7.13e-05	0.0145	CbGpPWpGaD
Amcinonide—Pruritus—Lisinopril—systemic scleroderma	6.91e-05	0.00204	CcSEcCtD
Amcinonide—Dermatitis—Mycophenolic acid—systemic scleroderma	6.83e-05	0.00202	CcSEcCtD
Amcinonide—ANXA1—Spinal Cord Injury—MMP9—systemic scleroderma	6.72e-05	0.0137	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—EDN1—systemic scleroderma	6.6e-05	0.0134	CbGpPWpGaD
Amcinonide—ANXA1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	6.42e-05	0.013	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	6.3e-05	0.0128	CbGpPWpGaD
Amcinonide—Dermatitis—Lisinopril—systemic scleroderma	6.15e-05	0.00182	CcSEcCtD
Amcinonide—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.05e-05	0.00179	CcSEcCtD
Amcinonide—Infection—Prednisone—systemic scleroderma	5.76e-05	0.0017	CcSEcCtD
Amcinonide—NR3C1—AP-1 transcription factor network—MMP1—systemic scleroderma	5.54e-05	0.0113	CbGpPWpGaD
Amcinonide—ANXA1—Spinal Cord Injury—TGFB1—systemic scleroderma	5.54e-05	0.0113	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	5.49e-05	0.0112	CbGpPWpGaD
Amcinonide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.39e-05	0.00159	CcSEcCtD
Amcinonide—ANXA1—GPCR downstream signaling—RHOB—systemic scleroderma	5.31e-05	0.0108	CbGpPWpGaD
Amcinonide—NR3C1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	4.89e-05	0.00993	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—RHOB—systemic scleroderma	4.82e-05	0.0098	CbGpPWpGaD
Amcinonide—Infection—Methotrexate—systemic scleroderma	4.82e-05	0.00142	CcSEcCtD
Amcinonide—ANXA1—GPCR ligand binding—EDN1—systemic scleroderma	4.8e-05	0.00975	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—CCL2—systemic scleroderma	4.51e-05	0.00916	CbGpPWpGaD
Amcinonide—ANXA1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.31e-05	0.00875	CbGpPWpGaD
Amcinonide—Pain—Methotrexate—systemic scleroderma	4.15e-05	0.00122	CcSEcCtD
Amcinonide—Pruritus—Prednisone—systemic scleroderma	4.1e-05	0.00121	CcSEcCtD
Amcinonide—ANXA1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.77e-05	0.00766	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—SMAD7—systemic scleroderma	3.72e-05	0.00755	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—SMAD7—systemic scleroderma	3.68e-05	0.00748	CbGpPWpGaD
Amcinonide—Dermatitis—Prednisone—systemic scleroderma	3.65e-05	0.00108	CcSEcCtD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	3.45e-05	0.00702	CbGpPWpGaD
Amcinonide—Pruritus—Methotrexate—systemic scleroderma	3.43e-05	0.00101	CcSEcCtD
Amcinonide—ANXA1—GPCR ligand binding—CCL2—systemic scleroderma	3.28e-05	0.00666	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—MMP9—systemic scleroderma	3.22e-05	0.00655	CbGpPWpGaD
Amcinonide—Dermatitis—Methotrexate—systemic scleroderma	3.05e-05	0.000901	CcSEcCtD
Amcinonide—ANXA1—Signaling Pathways—RHOB—systemic scleroderma	2.85e-05	0.00579	CbGpPWpGaD
Amcinonide—NR3C1—Endoderm Differentiation—TGFB1—systemic scleroderma	2.72e-05	0.00553	CbGpPWpGaD
Amcinonide—ANXA1—GPCR downstream signaling—EDN1—systemic scleroderma	2.71e-05	0.00551	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—HSPG2—systemic scleroderma	2.69e-05	0.00546	CbGpPWpGaD
Amcinonide—NR3C1—AP-1 transcription factor network—TGFB1—systemic scleroderma	2.66e-05	0.0054	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—CSK—systemic scleroderma	2.59e-05	0.00527	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—EDN1—systemic scleroderma	2.46e-05	0.005	CbGpPWpGaD
Amcinonide—NR3C1—Generic Transcription Pathway—CTGF—systemic scleroderma	2.05e-05	0.00418	CbGpPWpGaD
Amcinonide—NR3C1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	1.8e-05	0.00366	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—SMAD7—systemic scleroderma	1.79e-05	0.00364	CbGpPWpGaD
Amcinonide—ANXA1—Signaling by GPCR—CCL2—systemic scleroderma	1.68e-05	0.00342	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—TNFSF13—systemic scleroderma	1.66e-05	0.00338	CbGpPWpGaD
Amcinonide—NR3C1—Adipogenesis—TGFB1—systemic scleroderma	1.62e-05	0.00329	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—EDN1—systemic scleroderma	1.45e-05	0.00295	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—CCL2—systemic scleroderma	9.94e-06	0.00202	CbGpPWpGaD
Amcinonide—NR3C1—Gene Expression—CTGF—systemic scleroderma	9.89e-06	0.00201	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—NOS3—systemic scleroderma	8.86e-06	0.0018	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—MMP9—systemic scleroderma	7.11e-06	0.00144	CbGpPWpGaD
Amcinonide—ANXA1—Signaling Pathways—TGFB1—systemic scleroderma	5.86e-06	0.00119	CbGpPWpGaD
